Generic Savings: REMS Obstruction, Not ANDA Backlog, Is Main Hindrance, AAM Says
Executive Summary
Association for Accessible Medicines report highlights continuing upward trend of cost savings from generic drugs; trade group argues legislative proposals addressing restricted distribution misuse are key to accelerating savings.
You may also be interested in...
Congress Can Find Consensus On Drug Pricing By Targeting Cost Drivers – Waxman
Former Rep. Henry Waxman, D-Cal., discusses prospects for legislation on drug pricing, suggesting President Trump's comments on issue provide Congress an 'opportunity' to pursue change.
FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting
US agency is seeking feedback from interested stakeholders about administrative steps it can take to better promote generic competition; July 18 meeting will involve only presentations from the public.
FDA's Generic Policy Initiative Includes Choose-Your-Own-Agenda Meeting
US agency is seeking feedback from interested stakeholders about administrative steps it can take to better promote generic competition; July 18 meeting will involve only presentations from the public.